NASDAQ: PDSB · Life Sciences · 8 alerts · CIK 1472091
Share price
$0.9241Close, Nov 16
Market cap
$97M
Shares outstanding
105.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All PDS Biotechnology Corp filings on SEC EDGAR ↗
NantWorks exercised outstanding common stock warrants to purchase 17,699,115 shares of PDS Biotechnology at an exercise price of $0.22 per share. The transaction generated approximately $3.9 million in gross proceeds for the company. PDS Biotech intends to use the funds to advance its PDS0301 program toward a Phase 3 trial in metastatic colorectal cancer and for general corporate purposes.
PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.
PDS Biotechnology announced the publication of Phase 2 VERSATILE-002 trial results in JAMA Oncology, evaluating PDS0101 in combination with pembrolizumab for HPV16-positive head and neck cancer. The study reported a median overall survival of 39.3 months in ICI-naïve patients, significantly exceeding the 17.9 months typically seen with standard-of-care pembrolizumab. The treatment was well-tolerated with a 13.8% rate of Grade 3 or higher treatment-related adverse events.
PDS Biotechnology completed the initial closing of a PIPE financing led by Nant Capital, raising $11.3 million in gross proceeds through the sale of common stock and warrants. The company also announced a contingent milestone closing for an additional $11 million and appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. Proceeds will be used to repay $4.6 million in debt to Yorkville and advance the PDS0301 clinical program.